Aspirin in diabetic patients at primary prevention: insights of the VITAL cohort.

ABSTRACT:

Purpose

Aspirin use among patients with diabetes in primary prevention is still a matter of debate. We aimed to evaluate the potential cardiovascular risk benefit of aspirin in primary prevention, using data from a contemporary cohort.

Methods

Retrospective analysis of the VITAL cohort with > 20,000 individuals at primary prevention who were followed for a median of 5.3 years. The population was evaluated according to the baseline diabetes status, and then aspirin use was evaluated among diabetic patients. Cox regression models were used to estimate the risks of mortality and cardiovascular outcomes. The estimates were reported using adjusted hazard ratio (HR) and 95% confidence intervals (95%CI).

Results

Diabetic patients (n = 3549; 13.7%) showed to increase the risk

SUBMITTER: Caldeira D 

PROVIDER: S-EPMC10261209 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature